2023
Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria
Ivanics T, Claasen M, Samstein B, Emond J, Fox A, Pomfret E, Pomposelli J, Tabrizian P, Florman S, Mehta N, Roberts J, Emamaullee J, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff K, Hoteit M, Heimbach J, Taner T, Liapakis A, Mulligan D, Sapisochin G, Halazun K, Group O. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria. Annals Of Surgery 2023, 279: 104-111. PMID: 37522174, DOI: 10.1097/sla.0000000000006049.Peer-Reviewed Original ResearchConceptsUniversity of California San FranciscoMilan criteriaDonor liver transplantationHepatocellular carcinomaOverall survivalLiver transplantationPosttransplantation survivalEvaluate long-term oncologic outcomesUniversity of California San Francisco criteriaLiving donor liver transplantationRecurrence-free survivalKaplan-Meier methodTransplant selection criteriaProportion of patientsAdult LDLT recipientsNorth American centersLong-term survivalLiver transplant waitlistCalifornia San FranciscoLDLT recipientsMulticenter cohortConsensus guidelinesTransplantationPatientsPosttransplantation
2019
Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death
Valentino PL, Emre S, Geliang G, Li L, Deng Y, Mulligan D, Rodriguez-Davalos M. Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death. American Journal Of Transplantation 2019, 19: 3114-3123. PMID: 31152483, DOI: 10.1111/ajt.15481.Peer-Reviewed Original ResearchConceptsAdult recipientsTransplantation Network/United NetworkNumber of allograftsOrgan Sharing dataSplit-liver transplantationCareful patient selectionDeceased donor liversNumber of LTLT graftSLT recipientsUnderwent LTWLT recipientsPediatric candidatesPatient selectionDonor liversOrgan utilizationUnited NetworkOrgan shortageOrgan procurementSmall childrenRecipientsTransplantation
2016
The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond
Mulligan D. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond. Hepatology 2016, 64: 1853-1855. PMID: 27641833, DOI: 10.1002/hep.28841.Peer-Reviewed Original Research
2015
Disparity, Liver Demand, and Access to Transplants
Mulligan D. Disparity, Liver Demand, and Access to Transplants. American Journal Of Transplantation 2015, 15: 1746-1747. PMID: 25929170, DOI: 10.1111/ajt.13302.Peer-Reviewed Original Research
2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2008
Living donor liver transplantation in polycystic liver disease
Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, Mulligan DC. Living donor liver transplantation in polycystic liver disease. Liver Transplantation 2008, 14: 680-683. PMID: 18433036, DOI: 10.1002/lt.21423.Peer-Reviewed Original ResearchConceptsPolycystic liver diseaseDonor liver transplantationLiver transplantationLiver diseaseLiver functionEnd-Stage Liver Disease (MELD) systemDeceased donor liver transplantDonor liver transplantLiver transplantCaval resectionPoor qualityMassive hepatomegalyPatient survivalLiving donationPatientsHepatomegalyTransplantationHepatectomyDiseaseIdeal optionLDLTResectionComplicationsTransplantGraft
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
2005
Regional Variations in Peer Reviewed Liver Allocation Under the MELD System
Rodriguez‐Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional Variations in Peer Reviewed Liver Allocation Under the MELD System. American Journal Of Transplantation 2005, 5: 2244-2247. PMID: 16095504, DOI: 10.1111/j.1600-6143.2005.01008.x.Peer-Reviewed Original Research
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantationLiver transplantation for hepatocellular carcinoma: The MELD impact
Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez‐Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004, 10: 36-41. PMID: 14755775, DOI: 10.1002/lt.20012.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationNew allocation policyHCC candidatesPerson yearsIncidence rateHepatocellular carcinomaLiver transplantationUNOS databaseEnd-stage liver diseaseT2 hepatocellular carcinomaDonor liver transplantationDropout rateDate of implementationHepatic decompensationNew MELDClinical deteriorationMELD scoreLiver diseaseStage T1United NetworkOrgan SharingWaiting listSurvivalTransplantationCarcinoma